Kristie L. Kahl

Although hot flashes are most commonly associated with menopause, this uncomfortable feeling can also be a side effect that occurs in patients with cancer who are being treated with hormone therapy.

A recent study highlighted the additional psychological effects that patients with locally advanced cutaneous melanoma go through, particularly because their lesions are a visible part of their everyday life.

In recent years, major advances have been made in the immunotherapy scape, as it has become instrumental in revolutionizing the way oncologists treat a variety of cancers. However, its success in patients with brain cancer has been extremely limited.

“Regardless of their prognosis, they want to live, and they want to live their normal life. They don’t want it to be what defines them and live their life to the fullest. So, that is where technology can really be helpful," said Savitiri Basavaiah, of Pfizer Oncology.

As genetic testing becomes more accessible with advanced technology and decreased costs, population-based testing for breast and ovarian cancer may be more cost effective in the long run, according to study results published in Journal of the National Cancer Institute.

Kymriah, which is the first FDA-approved CAR-T cell therapy, is showing promising results in pediatric patients with acute lymphoblastic leukemia.

As the Philadelphia Eagles and New England Patriots fight for claim over the Super Bowl trophy tonight, two lung cancer survivor advocates are in Minneapolis fighting for another reason: to raise research and awareness dollars.

Microsatellite instability (MSI) status appeared to have no association with outcomes in patients with liver metastases that spread from colorectal cancer (CRC), according to results from an international, multi-institutional analysis presented at the 2018 Gastrointestinal Cancers Symposium.

“Adding HIPEC to interval debulking improved both recurrence free survival and overall survival without increasing morbidity,” said van Driel.

After patients have exhausted all therapeutic options in their cancer treatment, oftentimes there is nowhere left for them to turn. Despite a terminal diagnosis, some patients may have more options in their remaining days if one bill is passed – if only it were that easy.

Brain HQ, founded by Posit Science, is a computerized brain training program, designed to improve speed of processing information and accuracy in the brain.

Additional physical and mental components may seriously affect health-related quality of life in older patients with cancer.

Because physical activity after diagnosis has proven to lower mortality rates in these patients, it is important to implement feasible and acceptable interventions after CRC diagnoses.

CURE spoke with Scott Paulson, M.D., medical oncologist with Texas Oncology, an affiliate of The US Oncology Network, to break down exactly what MSI-H status is, and the effects it may have on certain malignancies.

As costs decrease, and physicians move to address barriers to genetic testing, a panel of physicians, researchers and a patient advocate highlighted the importance for people to get tested.

Patients with microsatellite instability-high (MSI-H) colorectal cancer may undergo a distinct pattern of clonal evolution, which in turn, would impact the use of targeted and immunologic therapies in these patients, according to study results presented at the 2018 Gastrointestinal Cancer Symposium.

Patients previously treated for DNA mismatch repair (MMR)-deficient/microsatellite instability-high (MSI-H) metastatic colorectal cancer may have a new effective treatment option.

Texas Rangers third-base coach Tony Beasley teams up with Fight CRC, sharing his journey into survivorship and inspiring others in their fight against cancer.

Even when a patient thinks they may have exhausted their very last treatment option, the Targeted Agent and Profiling Utilization Registry (TAPUR) Study is just the thing they may need.

Man’s best friend has joined the fight against cancer by significantly helping families of children undergoing treatment.

Clinical trials designed to evaluate the use of anti-cancer drugs for the treatment of cancer typically exclude patients whose disease has spread to the brain or CNS for a number of reasons, including the misperception that they are poor clinical trial candidates.

A study, conducted at Penn State College of Medicine, demonstrated that patients with melanoma who received immunotherapy while also taking a specific type of beta blocker lived longer than those who received immunotherapy alone.

Over the past few years, the Food and Drug Administration (FDA) has approved a variety of triplet combinations for the treatment of patients with multiple myeloma. However, little is known which regimens have the best economic impact, without sacrificing clinical outcomes that is.

The oldest cases of multiple myeloma and breast cancer date back to ancient Egyptian mummies.

The FDA approved a new combination for patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL).

Using the generic skin cream fluorouacil 5 percent (5-FU) for two to four weeks may reduce the risk for squamous cell carcinoma (SCC) for up to a year, according to a study published in JAMA Dermatology.

Oral mucositis causes pain, the inability to eat which can also lead to nutritional problems, and an increased risk for infection as a result of open sores. In turn, these symptoms can lead to reduced quality of life, chemotherapy or radiation dose-limiting, and increased treatment costs from antibiotics or narcotics or additional or longer hospital stays.

The researchers noted that physical activity plays an important role in lymphoma survivorship, and the data may provide rationale for a clinical trial to evaluate exercise intervention in this patient population.

Adequate end-of-life care derives a variety of benefits for both patients and their families, including less invasive and ineffective intervention and less financial burden, said study author Justin Jordan, M.D., MPH, clinical director of the Pappas Center for Neuro-Oncology at Massachusetts General Hospital (MGH) Cancer Center.

Patients with blood cancers are at an increased risk for multiple hospital readmissions. However, multidisciplinary teams and patients can work together to identify predictors and avoid these occurrences.